Acomprehensivetestforyourpatientswith

ThromboticMicroangiopathiesOR

C3Glomerulopathies

GeneticRenalPanel

GeneticRenalPanel

ADAMTS13(ADisintegrinandMetalloproteinasewithaThrombospondinType1Motif,member13)

C3(ComplementComponent3)

CFB(ComplementFactorB)

CFH(ComplementFactorH)

CFHR5(ComplementFactorHRelated5)

CFI(ComplementFactorI)

DGKE(DiacylglycerolKinase,Epsilon)

G6PD(Glucose‐6‐phosphatedehydrogenase)

MCP(MembraneCo‐FactorProteinorCD46)

MMACHC(MethylmalonicAciduria(CobalaminDe iciency)CblCType,WithHomocystinuria)

PLG(Plasminogen)

THBD(Thrombomodulin)

MLPA(CFH‐CFHR5genomicregionCNVanalysis)

GeneticRenalPanelSolveRateHigh‐ThroughputGeneticTestingforThromboticMicroangiopathiesandC3Glomerulopathies,FengxiaoBuet.al,JAmSocNephrol27:1245–1253,2016.doi:10.1681/ASN.2015040385

MolecularOtolaryngologyandRenalResearchLaboratories

Director:RichardJ.H.Smith,M.D.

Contact:AmyWeaver,ProjectAssistant

morl@uiowa.edu

Website:https://morl.lab.uiowa.edu

Inthepast,personsdiagnosedwithcomplement‐mediatedkidneydiseaserequiredmultipleteststoattempttoidentifythegeneticcauseoftheirdisease.TheGeneticRenalPanelisacomprehensivetestforpatientswith:

ThromboticMicroangiopathies(TMAs)

Thromboticthrombocytopenicpurpura(TTP)

Complement‐mediateddisease(aHUS) G6PDde iciency Cobalaminde iciency

C3Glomerulopathy(C3G)

DenseDepositDisease(DDD)

C3Glomerulonephritis(C3GN)

G

Helping you solve the puzzle of complement-mediated diseases

Toordercomprehensivetestingforyourpatientpleasevisitourwebsiteat:

https://morl.lab.uiowa.edu

TheUniversityofIowaMolecularOtolaryngology&RenalResearchLaboratoriesofferstheGeneticRenalPanel‐onetestthatis:

Comprehensive–testsforallgenesknowntobeassociatedwithavarietyofTMAs,andC3Gs.

Easy–patientprovidesonebloodsample.

Fast–averageturnaroundtimeof21days.

Convenient–bloodsampleistakeninlocaldoctor’soffice.

Accurate–99%analyticalspecificity.

Diagnostic–providesadiagnosisandguidetotreatment,transplantationandgeneticcounseling.

Personalized–resultsarediscussedatamultidisciplinarymeetingthatincludesphysicians,clinicalexperts,scientistsandbioinformaticians.

Collaborative–MORLwillworkdirectlywithyourphysicianorgeneticcounselortoensurethattestresultsareinterpretedaccurately.

Inexpensiveandef icient–onetestversusmanytests.

A comprehensive evaluation of the complementsystem requires four types of data to offer toyour patient the best chance of accuratelyde ining the cause and consequence ofcomplementdysregulation.

MeasuringComplementFunction–Measuringandfollowingcomplementactivitycanpredictdiseasestatus(activevs.inactive)andresponsetotherapy.

ComplementBiomarkerPro iling–Speci icbiomarkersprovideadetailedandmechanisticunderstandingoftheunderlyingcomplementpathologytoaddtodiseasede inition.Byde iningacomplementpathwaysignature,biomarkerscanbeusefultofollowdiseaseactivityand/orseverityintheclinicalsetting.

IdentifyingAcquiredDriversofDisease–IdentifyingacquireddriversofdiseasesuchasantibodiestotheC3convertase,factorHandfactorBprovidesametrictofollowapatient’sclinicalcourse.

A G R P

Spectrumofvariantsidenti iedusingtheGeneticRenalPanelHigh‐ThroughputGeneticTestingforThromboticMicroangiopathiesandC3Glomerulopathies,FengxiaoBuet.al,JAmSocNephrol27:1245–1253,2016.doi:10.1681/ASN.2015040385

Disease Group

Genetictestingprovidesimportantanswerstomanyquestions.Informationcanbeprovidedonrecurrencerisk,prognosis(whetheratransplantmightbesuccessfulorwhattypeoftransplantisnecessary,i.e.kidneyonlyorliver/kidney),andbestmethodsoftreatment.